The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030

Roots Analysis has done a detailed study on Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

Key Market Insights

§  Over 80 companies are offering antibody discovery services; of these, more than 75 players claim to offer services related to hit generation.

§  Nearly 180 innovative technology platforms have been developed by numerous firms for the purpose of antibody discovery.

§  Majority of stakeholders in the competitive market landscape are small / mid-sized firms, catering to the needs of a diverse clientele.

§  In order to get an edge over their competitors in the industry, companies have established their presence in different regions across the globe.

§  The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on antibody discovery for diverse range of indications.

§  Efforts of the players in the field of antibody discovery have garnered significant interest of several venture capital investors.

§  The antibody discovery services market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various steps involved in antibody discovery, antibody discovery method, nature of antibody generated and geographies.

§  The market for antibody discovery platforms is currently being driven by the revenues from the licensing deals; it is anticipated to reach USD 5.9 billion by 2030.

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

Table of Contents

1.         PREFACE

1.1.        Scope of the Report

1.2.        Research Methodology

1.3.        Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Structure of Antibodies

3.3.       History of Development

3.4.       Antibody Isotypes

3.5.       Mechanism of Action of Antibodies

3.6.       Classification of Antibodies

3.6.1.    Monoclonal Antibodies

3.6.2.    Polyclonal Antibodies

3.6.3.    Bispecific Antibodies

3.7.       Applications of Antibodies

Press Release: Variation 2 (Format 3)

4.         ANTIBODY DISCOVERY PROCESS AND METHODS

4.1.       Chapter Overview

4.2.       Antibody Discovery Process

4.2.1.    Target Selection and Validation

4.2.2.    Hit Generation

4.2.3.    Lead Selection

4.2.4.    Lead Optimization

4.2.4.1. Humanization

4.2.4.2. Affinity Maturation

4.2.4.3. Fc Engineering

4.2.5.    Lead Characterization

4.2.6.    Candidate Selection

4.3.       Antibody Discovery Methods

4.3.1.    Hybridoma Method

4.3.2.    In vitro Display Method

4.3.2.1. Phage Display

4.3.2.2. Yeast Display

4.3.2.3. Ribosomal Display

4.3.3.    Transgenic Animal-Based Method

4.3.4.    Single B Cell-Based Method

4.3.5.    Advantages and Disadvantages of Existing Antibody Discovery Techniques

4.4.       Evolution of Monoclonal Antibodies

4.4.1.    Fully Human Monoclonal Antibodies

5.         ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

5.1.       Chapter Overview

5.2.       Antibody Discovery Service Providers: List of Industry Players

5.2.1.    Analysis by Year of Establishment

5.2.2.    Analysis by Company Size

5.2.3.    Analysis by Location of Headquarters

5.2.4.    Analysis by Type of Service Offered

5.2.5.    Analysis by Type of Antibody Discovery Method

5.2.6.    Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size

5.2.7.    Analysis by Animal Model Used

5.2.8.    Analysis by Type of Antibody Discovered

5.2.9.    Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered

5.2.10.  Analysis by Purpose of Antibody Discovery

5.2.11.  Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery

6.         COMPANY COMPETITIVENESS ANALYSIS

6.1.       Chapter Overview

6.2.       Methodology

6.3.       Key Parameters

6.4.       Competitiveness Analysis: Antibody Discovery Service Providers

6.4.1.    Antibody Discovery Service Providers based in North America

6.4.2.    Antibody Discovery Service Providers based in Europe

6.4.3.    Antibody Discovery Service Providers based in Asia Pacific

7.         COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

7.1.       Chapter Overview

7.2.       Antibody Discovery Service Providers in North America

7.2.1.    Abwiz Bio

7.2.1.1. Company Overview

Press Release: Variation 2 (Format 3)

7.2.1.2. Antibody Discovery Services

7.2.1.3. Recent Developments and Future Outlook

7.2.2.    Aragen Bioscience (A GVK BIO Company)

7.2.2.1. Company Overview

7.2.2.2. Antibody Discovery Services

7.2.2.3. Recent Developments and Future Outlook

7.2.3.    Distributed Bio

7.2.3.1. Company Overview

7.2.3.2. Antibody Discovery Services

7.2.3.3. Recent Developments and Future Outlook

7.2.4.    Integral Molecular

7.2.4.1. Company Overview

7.2.4.2. Antibody Discovery Services

7.2.4.3. Recent Developments and Future Outlook

7.2.5.    LakePharma

7.2.5.1. Company Overview

7.2.5.2. Antibody Discovery Services

7.2.5.3. Recent Developments and Future Outlook

7.3.       Antibody Discovery Service Providers in Europe

7.3.1.    Abzena

7.3.1.1. Company Overview

7.3.1.2. Financial Information

7.3.1.3. Antibody Discovery Services

7.3.1.4. Recent Developments and Future Outlook

7.3.2.    ImmunoPrecise Antibodies

7.3.2.1. Company Overview

7.3.2.2. Financial Information

7.3.2.3. Antibody Discovery Services

7.3.2.4. Recent Developments and Future Outlook

7.3.3.    PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)

7.3.3.1. Company Overview

7.3.3.2. Antibody Discovery Services

7.3.3.3. Recent Developments and Future Outlook

7.4.       Antibody Discovery Service Providers in Asia-Pacific

7.4.1.    ChemPartner

7.4.1.1. Company Overview

7.4.1.2. Antibody Discovery Services

7.4.1.3. Recent Developments and Future Outlook

7.4.2.    Viva Biotech

7.4.2.1. Company Overview

7.4.2.2. Financial Information

7.4.2.3. Antibody Discovery Services

7.4.2.4. Recent Developments and Future Outlook

7.4.3.    WuXi Biologics

7.4.3.1. Company Overview

7.4.3.2. Financial Information

Press Release: Variation 2 (Format 3)

7.4.3.3. Antibody Discovery Services

7.4.3.4. Recent Developments and Future Outlook

8.         ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE

8.1.       Chapter Overview

8.2.       Antibody Discovery Platform Providers: List of Industry Players

8.2.1.    Analysis by Year of Establishment

8.2.2.    Analysis by Company Size

8.2.3.    Analysis by Location of Headquarters

8.2.4.    Analysis by Type of Antibody Discovered

8.3.       Antibody Discovery: List of Technologies and Platforms

8.3.1.    Analysis by Type of Antibody Discovery Method

8.3.2.    Analysis by Type of Antibody Discovery Method and Location of Headquarters

8.3.3.    Analysis by Animal Model Used

8.3.4.    Analysis by Patent Availability

9.         TECHNOLOGY COMPETITIVENESS ANALYSIS

9.1.       Chapter Overview

9.2.       Methodology

9.3.       Key Parameters

9.4.       Technology Competitiveness Analysis: Antibody Discovery Platforms

9.4.1.    Competitiveness Analysis: Library Based Antibody Discovery Platforms

9.4.2.    Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms

9.4.3.    Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms

9.4.4.    Competitiveness Analysis: Other Antibody Discovery Platforms

10.        COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

10.1.     Chapter Overview

10.2.     ImmunoPrecise Antibodies

10.2.1.  Company Overview

10.2.2.  Financial Information

10.2.3.  Portfolio of Antibody Discovery Platforms

10.2.3.1. Abthena™

10.2.3.2. B cell Select™

10.2.3.3. DeepDisplay™

10.2.3.4. ModiFuse™

10.2.3.5. ModiPhage™

10.2.3.6. ModiSelect™

10.2.3.7. ModiTune™

10.2.4.   Recent Developments and Future Outlook

10.3.     Harbour BioMed

10.3.1.  Company Overview

10.3.2.  Portfolio of Antibody Discovery Platforms

10.3.2.1. H2L2 Platform

10.3.2.2. HCAb Platform

10.3.3.   Recent Developments and Future Outlook

10.4.     Kymab

10.4.1.  Company Overview

10.4.2.  Portfolio of Antibody Discovery Platforms

10.4.2.1. Kymouse™

10.4.2.2. IntelliSelect®

10.4.3.   Recent Developments and Future Outlook

10.5.     Ligand Pharmaceuticals

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com